Investigational Three-Dose Lyme Vaccine Candidate Generates Immunogenicity, Appears Safe In Phase II Trials

MedPage Today (6/5, Kahn) reports, “An investigational three-dose Lyme vaccine (VLA15) against Borrelia outer surface protein A (OspA)-specific serotypes generated immunogenicity and appeared safe, according to results of two linked phase II trials.” With the administration of the vaccine “on a 0/2/6-month vaccine schedule (study two), OspA-specific IgG geometric mean titers (GMTs) ranged from 278.5 to 545.2 units/mL with the 135-μg vaccine dose at 1 month after the third dose, and 274.7 to 596.8 units/mL for the 180-μg dose, reported” researchers in The Lancet Infectious Diseases.